284 related articles for article (PubMed ID: 30305506)
1. [Dyserythropoiesis in myelodysplastic syndrome].
Iwama A
Rinsho Ketsueki; 2018; 59(10):2036-2041. PubMed ID: 30305506
[TBL] [Abstract][Full Text] [Related]
2. [Ineffective erythropoiesis in myelodysplastic syndrome].
Iwama A
Rinsho Ketsueki; 2018; 59(6):793-797. PubMed ID: 29973461
[TBL] [Abstract][Full Text] [Related]
3. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
4. PRC2 insufficiency causes p53-dependent dyserythropoiesis in myelodysplastic syndrome.
Aoyama K; Shinoda D; Suzuki E; Nakajima-Takagi Y; Oshima M; Koide S; Rizq O; Si S; Tara S; Sashida G; Iwama A
Leukemia; 2021 Apr; 35(4):1156-1165. PubMed ID: 32820269
[TBL] [Abstract][Full Text] [Related]
5. Dyserythropoiesis of myelodysplastic syndromes.
Lefèvre C; Bondu S; Le Goff S; Kosmider O; Fontenay M
Curr Opin Hematol; 2017 May; 24(3):191-197. PubMed ID: 28072603
[TBL] [Abstract][Full Text] [Related]
6. Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL; Mortera-Blanco T; Hofman IJ; Todisco G; Kretzschmar WW; Björklund AC; Creignou M; Hagemann-Jensen M; Ziegenhain C; Cabrerizo Granados D; Barbosa I; Walldin G; Jansson M; Ashley N; Mead AJ; Lundin V; Dimitriou M; Yoshizato T; Woll PS; Ogawa S; Sandberg R; Jacobsen SEW; Hellström-Lindberg E
Cancer Res; 2024 Jan; 84(2):211-225. PubMed ID: 37921711
[TBL] [Abstract][Full Text] [Related]
7. SF3B1 deficiency impairs human erythropoiesis via activation of p53 pathway: implications for understanding of ineffective erythropoiesis in MDS.
Huang Y; Hale J; Wang Y; Li W; Zhang S; Zhang J; Zhao H; Guo X; Liu J; Yan H; Yazdanbakhsh K; Huang G; Hillyer CD; Mohandas N; Chen L; Sun L; An X
J Hematol Oncol; 2018 Feb; 11(1):19. PubMed ID: 29433555
[TBL] [Abstract][Full Text] [Related]
8. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
9. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
10. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts.
Mupo A; Seiler M; Sathiaseelan V; Pance A; Yang Y; Agrawal AA; Iorio F; Bautista R; Pacharne S; Tzelepis K; Manes N; Wright P; Papaemmanuil E; Kent DG; Campbell PC; Buonamici S; Bolli N; Vassiliou GS
Leukemia; 2017 Mar; 31(3):720-727. PubMed ID: 27604819
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
12. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Malcovati L; Stevenson K; Papaemmanuil E; Neuberg D; Bejar R; Boultwood J; Bowen DT; Campbell PJ; Ebert BL; Fenaux P; Haferlach T; Heuser M; Jansen JH; Komrokji RS; Maciejewski JP; Walter MJ; Fontenay M; Garcia-Manero G; Graubert TA; Karsan A; Meggendorfer M; Pellagatti A; Sallman DA; Savona MR; Sekeres MA; Steensma DP; Tauro S; Thol F; Vyas P; Van de Loosdrecht AA; Haase D; Tüchler H; Greenberg PL; Ogawa S; Hellstrom-Lindberg E; Cazzola M
Blood; 2020 Jul; 136(2):157-170. PubMed ID: 32347921
[TBL] [Abstract][Full Text] [Related]
13. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.
Visconte V; Tabarroki A; Zhang L; Parker Y; Hasrouni E; Mahfouz R; Isono K; Koseki H; Sekeres MA; Saunthararajah Y; Barnard J; Lindner D; Rogers HJ; Tiu RV
J Hematol Oncol; 2014 Dec; 7():89. PubMed ID: 25481243
[TBL] [Abstract][Full Text] [Related]
14. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
[TBL] [Abstract][Full Text] [Related]
15. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.
Obeng EA; Chappell RJ; Seiler M; Chen MC; Campagna DR; Schmidt PJ; Schneider RK; Lord AM; Wang L; Gambe RG; McConkey ME; Ali AM; Raza A; Yu L; Buonamici S; Smith PG; Mullally A; Wu CJ; Fleming MD; Ebert BL
Cancer Cell; 2016 Sep; 30(3):404-417. PubMed ID: 27622333
[TBL] [Abstract][Full Text] [Related]
16. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes.
Lieu YK; Liu Z; Ali AM; Wei X; Penson A; Zhang J; An X; Rabadan R; Raza A; Manley JL; Mukherjee S
Proc Natl Acad Sci U S A; 2022 Jan; 119(1):. PubMed ID: 34930825
[TBL] [Abstract][Full Text] [Related]
17. Clonal shifts in MDS - from SF3B1 to EZH2.
Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
[No Abstract] [Full Text] [Related]
18. Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in
Mian SA; Philippe C; Maniati E; Protopapa P; Bergot T; Piganeau M; Nemkov T; Di Bella D; Morales V; Finch AJ; D'Alessandro A; Bianchi K; Wang J; Gallipoli P; Kordasti S; Kubasch AS; Cross M; Platzbecker U; Wiseman DH; Bonnet D; Bernard DG; Gribben JG; Rouault-Pierre K
Sci Transl Med; 2023 Mar; 15(685):eabn5135. PubMed ID: 36857430
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis with Cooccurrent SF3B1 and MPL Gene Mutations: A Case Report and Brief Review of the Literature.
Park CH; Yun JW; Kim HY; Lee KO; Kim SH; Kim HJ
Lab Med; 2020 May; 51(3):315-319. PubMed ID: 31858134
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
